Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

Immune checkpoint inhibitors and adoptive lymphocyte transfer–based therapies have shown great therapeutic potential in cancers with high tumor mutational burden (TMB), such as melanoma, but not in cancers with low TMB, such as mutant epidermal growth factor receptor (EGFR)–driven lung adenocarcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yue A., Maity, Tapan K., Cultraro, Constance M., Misra, Vikram, Zhang, Xu, Ade, Catherine, Gao, Shaojian, Milewski, David, Nguyen, Khoa D., Ebrahimabadi, Mohammad H., Hanada, Ken-ichi, Khan, Javed, Sahinalp, Cenk, Yang, James C., Guha, Udayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724932/
https://www.ncbi.nlm.nih.gov/pubmed/34391887
http://dx.doi.org/10.1016/j.mcpro.2021.100136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724932/
https://www.ncbi.nlm.nih.gov/pubmed/34391887
http://dx.doi.org/10.1016/j.mcpro.2021.100136

Ejemplares similares